文献速递类风湿关节炎

阿达木单抗减量治疗长期临床缓解类风湿关节炎患者的IV期PREDICTRA研究结果

Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.
PubMed 文献 · Ann Rheum Dis · 2020-05-13

PREDICTRA研究纳入接受阿达木单抗40mg隔周治疗且持续缓解≥6个月的RA患者,经4周开放导入后按5:1随机分为减量组(每3周一次)和撤药组(安慰剂)治疗36周。减量组36%和撤药组45%患者出现复发,基线MRI炎症与复发无关,约半数复发患者经16周开放救援阿达木单抗后恢复临床缓解。

要点

  • 持续缓解的RA患者阿达木单抗减量后36周内约三分之一复发,撤药后约半数复发。
  • 基线疾病特征及阿达木单抗浓度均与减量后复发无关。
  • 约半数复发患者经16周开放救援阿达木单抗后恢复临床缓解。

核心结论

  • 减量阿达木单抗的患者约三分之一在36周内复发,而撤药患者约半数复发。
  • 减量组复发时间数值上长于撤药组(18.0周 vs 13.3周)。
  • 基线MRI检测的炎症与减量后复发发生无关。

研究设计与样本

  • PREDICTRA为IV期随机双盲研究,纳入接受阿达木单抗40mg隔周治疗且持续缓解≥6个月的RA患者。
  • 经4周开放导入后,患者按5:1随机分为双盲阿达木单抗减量组(每3周一次,n=102)或撤药组(安慰剂,n=20)治疗36周。
  • 主要终点为双盲基线手和腕MRI检测的炎症与复发发生的关联。

主要发现

  • 146例患者接受开放导入治疗,122例被随机分配至减量组(n=102)或撤药组(n=20)。
  • 患者平均活动性疾病病程12.9年,平均接受阿达木单抗治疗5.4年(平均持续缓解2.2年)。
  • 减量组37例(36%)和撤药组9例(45%)患者出现复发,复发时间分别为18.0周和13.3周。
  • 双盲基线疾病特征或阿达木单抗浓度均与减量后复发发生无关。
  • 约半数复发患者经16周开放救援阿达木单抗后恢复临床缓解,安全性特征与既往研究一致。

临床怎么用

  • 对持续缓解的RA患者,阿达木单抗减量至每3周一次较撤药可降低36周内复发风险。
  • 基线MRI炎症及药物浓度不宜单独用于预测减量后复发。
  • 减量后复发患者可通过恢复阿达木单抗治疗使约半数恢复临床缓解。

局限性

  • 撤药组样本量较小(n=20),减量组与撤药组样本量不平衡(5:1)。
  • 研究未报告基线MRI炎症与复发关联的具体效应量或统计检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the association between baseline disease activity and the occurrence of flares after adalimumab tapering or withdrawal in patients with rheumatoid arthritis (RA) in sustained remission. METHODS: The PREDICTRA phase IV, randomised, double-blind (DB) study (ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels, and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Patients) enrolled patients with RA receiving adalimumab 40 mg every other week who were in sustained remission ≥6 months. After a 4-week, open-label lead-in (OL-LI) period, patients were randomised 5:1 to DB adalimumab taper (every 3 weeks) or withdrawal (placebo) for 36 weeks. The primary endpoint was the association between DB baseline hand and wrist MRI-detected inflammation with flare occurrence. RESULTS: Of 146 patients treated during the OL-LI period, 122 were randomised to taper (n=102) or withdrawal (n=20) arms. Patients had a mean 12.9 years of active disease and had received adalimumab for a mean of 5.4 years (mean 2.2 years in sustained remission). Overall, 37 (36%) and 9 (45%) patients experienced a flare in the taper and withdrawal arms, respectively (time to flare, 18.0 and 13.3 weeks). None of the DB baseline disease characteristics or adalimumab concentration was associated with flare occurrence after adalimumab tapering. Approximately half of the patients who flared regained clinical remission after 16 weeks of open-label rescue adalimumab. The safety profile was consistent with previous studies. CONCLUSIONS: Approximately one-third of patients who tapered adalimumab versus half who withdrew adalimumab experienced a flare within 36 weeks. Time to flare was numerically longer in the taper versus withdrawal arm. Baseline MRI inflammation was not associated with flare occurrence. TRIAL REGISTRATION NUMBER: NCT02198651, EudraCT 2014-001114-26.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Emery P, Burmester GR, Naredo E, et al. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. Ann Rheum Dis. 2020. PMID: 32404343. doi:10.1136/annrheumdis-2020-217246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。